Kliman Gilbert H sold $475K of GKOS

Kliman Gilbert H sold 2,500 shares of GLAUKOS Corp (GKOS) at $190.00 ($0.48M total) on 2026-08-19.

Original reporting
SEC EDGAR · Kliman Gilbert H
Published Aug 21, 2026, 12:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The director's sale is modest and unlikely to move the stock. Investors should monitor larger insider activity for stronger signals.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

No indication of upcoming corporate actions or earnings that would affect the stock.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-20 after market close

Background

Glaukos Corp (GKOS) is a medical device company focused on ophthalmic treatments. Insider transactions are publicly disclosed via Form 4.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Director Kliman Gilbert H sold 2,500 shares of Glaukos Corp for $475,000 on 2026-08-19, reducing his holdings to 37,406 shares.

Expected impact

Minimal short-term price pressure; likely no significant move.

Evidence & confidence

The sale size ($475k) is below the materiality threshold for a mid‑cap stock and represents a routine 10b5‑1‑style transaction.

Market effects

None

None

None

Counterpoint

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • Glaukos Corp

    US‑listed ophthalmic device manufacturer (ticker GKOS).

  • Kliman Gilbert H

    Director of Glaukos Corp who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.